Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility. | April 14, 2023
Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosisMALVERN, Pa., April 11, 2023 . | April 11, 2023
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The Foundation Fighting Blindness, the world s leading organization committed to finding treatments and cures for blinding retinal diseases, in.
The Lobo Language Acquisition Lab presents #CelebrateBilingualismNM Speaker Series featuring Dr. Rain Bosworth on Friday, Dec. 2 from 12 to 1:30 p.m. The title of Bosworth’s talk is Learning about Language from Bimodal Babies: Insights from Eye Gaze.